Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Upper and/or lower extremity CRPS
• On stable treatment for 1 month
• CRPS for at least 1 year
• Meet the Budapest criteria for CRPS at time of the study.
Locations
United States
California
Stanford University
RECRUITING
Palo Alto
Contact Information
Primary
Birute Gedrimaite
birute@stanford.edu
(650) 497-0485
Time Frame
Start Date: 2015-06
Estimated Completion Date: 2027-07
Participants
Target number of participants: 120
Treatments
Experimental: LDN
Naltrexone HCL, 4.5 mg, Once a day.
Placebo_comparator: Placebo
Sugar pill
Related Therapeutic Areas
Sponsors
Leads: Stanford University